Applications for San Francisco (Batch 12) extended AGAIN through September 30th, 2021!

Learn more about investing in Pannex Therapeutics

Our team will get back to you soon to follow up on your inquiry.
Pannex Therapeutics
Developing anti-addictive painkillers to save lives.
Founded
2020
Employees*
1-10
Funding to Date*
$445K
Website
https://pannextherapeutics.com/
David Bravo, Ph.D., CEO
Chronic pain is is not a one single disease: it is estimated 20 to 30% of the entire world's population suffers some levels of chronic pain.
20 to 30% of the entire world's population suffers some levels of chronic pain.

Pannex Therapeutics is a pioneer biopharmaceutical company totally focused on the development of a novel therapeutic class of Pannexin 1 channel (Panx1) blockers. Pannex is developing a platform of small molecules that blocks this exciting new pharmacological target, Panx1 channels.

With potential applications in many therapeutic areas, the initial focus is on chronic pain treatment. The company is currently developing a first-in-class, selective and highly potent oral Panx1 channel blocker, for the treatment of chronic pain and prevention of opioid addiction.